Geron Corporation Reports Third Quarter 2018 Financial Results and Recent Company Events
November 01, 2018 16:05 ET
|
Geron Corporation
Imetelstat program transition proceeding, including plans to initiate Phase 3 portion of IMerge Abstracts for IMbark and IMerge accepted for oral presentation at American Society of Hematology...
Apellis Pharmaceuticals Announces Poster Presentations at the American Society of Hematology Annual Meeting
November 01, 2018 10:50 ET
|
Apellis Pharmaceuticals, Inc.
CRESTWOOD, Ky. and WALTHAM, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc. (Nasdaq:APLS), a clinical-stage biopharmaceutical company focused on the development of novel...
Geron Announces Two Oral Presentations on Imetelstat at Upcoming American Society of Hematology Annual Meeting
November 01, 2018 06:20 ET
|
Geron Corporation
Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes and IMbark Primary Analysis in Myelofibrosis to be Presented MENLO PARK, Calif., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Geron...
Geron Announces Discontinuation of Imetelstat Collaboration by Janssen
September 27, 2018 06:00 ET
|
Geron Corporation
Geron regains global rights to imetelstat programHighlights reported for IMerge and IMbarkGeron plans to initiate the Phase 3 portion of IMergeConference call scheduled for 8:00 a.m. ET today MENLO...
Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting
December 12, 2017 07:30 ET
|
Geron Corporation
Imetelstat Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes (MDS) Presented Analyst and Investor Meeting and Webcast at 8:30 a.m. ET on December 19, 2017 MENLO PARK, Calif., Dec. ...
Geron Announces First Patient Dosed in Expanded Part 1 of IMerge Clinical Trial in Myelodysplastic Syndromes
November 20, 2017 07:30 ET
|
Geron Corporation
MENLO PARK, Calif., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the first patient has been dosed in the expanded Part 1 of IMerge, the ongoing Phase 2/3...
Geron Announces Presentations at American Society of Hematology Annual Meeting
November 01, 2017 09:05 ET
|
Geron Corporation
MENLO PARK, Calif., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that four abstracts related to the telomerase inhibitor imetelstat have been accepted for...
Geron Reports Imetelstat Presentations at American Society of Hematology Annual Meeting
December 06, 2016 16:01 ET
|
Geron Corporation
MENLO PARK, Calif., Dec. 06, 2016 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced four presentations of exploratory preclinical and clinical data related to the imetelstat...
Apellis Reports Positive Interim Results from Phase 1b Clinical Trials of APL-2 in PNH
December 02, 2016 08:00 ET
|
Apellis Pharmaceuticals, Inc.
LOUISVILLE, Ky., Dec. 02, 2016 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on inhibition of the complement system, today will present...
CRISPR Therapeutics Announces Two Presentations Demonstrating the Potential for CRISPR Gene Editing To Treat Sickle Cell Disease and β-Thalassemia
November 21, 2016 08:00 ET
|
CRISPR Therapeutics AG
BASEL, Switzerland and CAMBRIDGE, Mass., Nov. 21, 2016 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines...